GlassScriptPhysician profile
Tanisha B Smith
NPI 1740541440
$17,444.83
in general payments reported to CMS, 2019-2025
53 companies · $2,114 in 2025
The $2,114 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,862 · 2022: $3,735 · 2023: $4,796 · 2024: $3,938 · 2025: $2,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,345 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,550 · Travel and Lodging: $514 · Consulting Fee: $430 · Education: $9.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,345.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,550.00 |
| Travel and Lodging | $514.15 |
| Consulting Fee | $430.00 |
| Education | $9.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,995.63 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $2,837.68 | 2021-2025 | |
| Global Blood Therapeutics, INC. | $2,230.94 | 2021-2022 | |
| Chiesi USA, INC. | $626.37 | 2022-2025 | Ferriprox |
| Janssen Biotech, INC. | $603.34 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $590.16 | 2021-2025 | Calquence, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $534.69 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $439.86 | 2021-2024 | |
| Incyte Corporation | $301.28 | 2021-2025 | Jakafi, Monjuvi |
| Ipsen Biopharmaceuticals, INC | $244.93 | 2021-2025 | Somatuline Depot, Onivyde, Tazverik |
| Daiichi Sankyo INC. | $216.81 | 2022-2025 | Enhertu, Datroway |
| Emmaus Medical, INC. | $215.51 | 2021-2025 | Endari |
| Takeda Pharmaceuticals U.S.A., INC. | $206.87 | 2022-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Beigene USA, INC. | $191.12 | 2021-2024 | Brukinsa |
| Amgen INC. | $172.48 | 2021-2023 | Kyprolis |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanisha Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.